NCT03354520

Brief Summary

The study is to maximize efficacy of message delivery to achieve desired Obstructive sleep apnea (OSA) adherence goal. Newly diagnosed black patients (n=390, all genders) from participating sleep clinics will be randomly exposed to either the individually tailored or standard OSA messages. Investigators will look at an effective and scalable intervention to improve OSA-related outcomes: a) clinical CVD and brain health measures and b) patient-centered outcomes. Patient-centered and adherence data will be captured via REDCap, enabling real-time application of data-driven decision rules while implementing the intervention.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 21, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 28, 2017

Completed
3.6 years until next milestone

Study Start

First participant enrolled

June 18, 2021

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 18, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 18, 2021

Completed
Last Updated

February 9, 2022

Status Verified

February 1, 2022

Enrollment Period

Same day

First QC Date

November 21, 2017

Last Update Submit

February 7, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline OSA Self-Efficacy Scale Score to 6 Months Score

    The mean of the nonmissing item responses was calculated for each of the 3 subscales: Perceived Risk, Outcome Expectancies, and Treatment Self-Efficacy. Using this mean-weighted score prevents the distortion of the score from missing responses. Factor 1 (Risk Perception consisting of 8 questions); Factor 2 (Outcome Expectancy consisting of 9 items) and Factor 3 (Treatment Self Efficacy consisting of 9 items) are given a potential score of 1-4.

    2 Months and 6 Months

Study Arms (3)

Tailored Videos

ACTIVE COMPARATOR
Behavioral: Tailored Videos

Standard Videos

ACTIVE COMPARATOR
Behavioral: Standard Videos

OSA Treatment

ACTIVE COMPARATOR
Behavioral: OSA Treatment

Interventions

Tailored VideosBEHAVIORAL

web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).

Tailored Videos
OSA TreatmentBEHAVIORAL

Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.

OSA Treatment
Standard VideosBEHAVIORAL

Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website

Standard Videos

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Self-reported race/ethnicity as African American, African, Caribbean or black
  • Accessible by phone
  • No plans to move away within the year
  • OSA diagnosis, consent, including permission to release medical data
  • Physician-diagnosed medical conditions.

You may not qualify if:

  • Progressive illnesses in which disability or death is expected within 1 year
  • Impaired cognitive/ functional ability precluding participation
  • Intention to move within the same year of enrollment
  • Family member currently enrolled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New York University School of Medicine

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Girardin Jean-Louis, PhD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 21, 2017

First Posted

November 28, 2017

Study Start

June 18, 2021

Primary Completion

June 18, 2021

Study Completion

June 18, 2021

Last Updated

February 9, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 3 months and ending 5 years following article publication.
Access Criteria
Requests should be directed to Ferdinand.Zizi@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Locations